Al/ZnO nanoparticle as an effective nanocarrier in delivery of lenalidomide anti-multiple myeloma cancer drug

ABSTRACT

Lenalidomide is a key drug in multiple myeloma. Moreover, Al-ZnO has garnered significant attention due to its distinct physicochemical characteristics. This investigation introduces an economic approach for fabrication and characterization of Al-ZnO nanoparticles by SEM, TEM, FT-IR, XPS, UV-VIS, EDS, and XRD techniques. Subsequently, the research explored capacity of the created nanostructure to serve as a nanocarrier for Lenalidomide. Findings indicated an approximate 71% drug loading capacity that is dependent on pH and duration time. The release profile depicted a gradual release under physiological conditions (pH 7.4, 28%), contrasting with a notably accelerated release rate at pH 6.2 (78%) in 48 h. Furthermore, an in vitro assessment of cellular cytotoxicity performed on U266 multiple myeloma cancer cell line to evaluate safety and effectiveness of Al-ZnO nanoparticles. Results from MTT assay affirmed the potential of this nanoparticle as a promising vehicle for Lenalidomide delivery.

KEYWORDS:

• Al-ZnO
• synthesis
• lenalidomide
• sensor
• gynaecology
• U266

Disclosure statement

No potential conflict of interest was reported by the author(s).

Data availability statement

The data that support the findings of this study are available from the corresponding author upon reasonable request.

Author contributions

L.Z. and C.Z.: experiments, Validation, and Data Curation. Q.Y.: Conceptualization, Investigation, Writing and editing. M.L.: Supervision, Writing and editing.